Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shill, H. A.
Right arrow Articles by Hallett, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shill, H. A.
Right arrow Articles by Hallett, M.
Related Collections
Right arrow Tremor
Right arrow All Clinical trials
Right arrow Clinical trials Observational study (Cohort, Case control)
NEUROLOGY 2004;62:2320-2322
© 2004 American Academy of Neurology
Brief Communications

Open-label dose-escalation study of oral 1-octanol in patients with essential tremor

H. A. Shill, MD, K. O. Bushara, MD, Z. Mari, MD, M. Reich and M. Hallett, MD

From the Human Motor Control Section (Drs. Shill, Mari, and Hallett, M. Reich), Medical Neurology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, and Minneapolis Veterans Affairs Medical Center (Dr. Bushara), MN.

Address correspondence and reprint requests to Dr. M. Hallett, Human Motor Control Section, National Institute of Neurological Disorders and Stroke, NIH, Bldg. 10, Rm. 5N226, 10 Center Dr., MSC 1428, Bethesda, MD 20892-1428; e-mail: hallettm{at}ninds.nih.gov

Twenty-one single oral doses of 1-octanol were given to patients with essential tremor (ET) in an open-label dose-escalation study. The drug was well tolerated up to 64 mg/kg. The main side effect was an unusual taste. No overt intoxication was seen. There was evidence for efficacy, with a significant reduction in tremor amplitude as measured by accelerometry and handwriting that was maximal at 2 hours. Higher doses may produce more sustained benefit.

Received September 25, 2003. Accepted in final form February 16, 2004.




This article has been cited by other articles:


Home page
 BrainHome page
A. G. Shaikh, K. Miura, L. M. Optican, S. Ramat, R. J. Leigh, and D. S. Zee
A new familial disease of saccadic oscillations and limb tremor provides clues to mechanisms of common tremor disorders
Brain, November 1, 2007; 130(11): 3020 - 3031.
[Abstract] [Full Text] [PDF]

Home page
 PNHome page
F. B Nahab, E. Peckham, and M. Hallett
Essential tremor, deceptively simple ...
Practical Neurology, August 1, 2007; 7(4): 222 - 233.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. Klebe, H. Stolze, K. Grensing, J. Volkmann, R. Wenzelburger, and G. Deuschl
Influence of alcohol on gait in patients with essential tremor
Neurology, July 12, 2005; 65(1): 96 - 101.
[Abstract] [Full Text] [PDF]

Home page
 JWatch PsychiatryHome page
A Potential New Treatment for Essential Tremor
Journal Watch Psychiatry, November 18, 2004; 2004(1118): 12 - 12.
[Full Text]

Home page
 JWatch NeurologyHome page
A Potential New Treatment for Essential Tremor
Journal Watch Neurology, September 23, 2004; 2004(923): 1 - 1.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.